Publications
Publications
Show Results For
- All HBS Web
(1,026)
- Faculty Publications (264)
Drug
→
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
- February 1993 (Revised August 1995)
- Case
Medicare Payment for Drugs and Medical Devices
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
- March 1992
- Case
Amgen, Inc.: Planning the Unplannable
By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,... View Details
- September 1991 (Revised February 1993)
- Case
Burroughs Wellcome and AZT (A)
Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S.... View Details
- October 1990 (Revised April 1991)
- Case
RU 486 (A)
Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details
- April 1989 (Revised May 1993)
- Case
Novel Combination of Two Drugs (A)
- April 1989
- Supplement
Novel Combination of Two Drugs (B)
- April 1989
- Supplement
Novel Combination of Two Drugs (C)
- April 1989 (Revised July 1992)
- Supplement
Technology Transfer: Anti-Inflammatory Drug (B)
- April 1989 (Revised July 1992)
- Supplement
Technology Transfer: Anti-Inflammatory Drug (C)
- March 1989 (Revised August 1989)
- Case
GI Wars: Tums vs. Rolaids—Positioning Over-the-Counter Drugs
- October 1987 (Revised November 1994)
- Case
Boston Fights Drugs (A): Designing Communications Research
Describes in detail the research mounted by five individuals with a $20,000 budget to combat drug abuse among Boston's school-going population. Using the focus group methodology they discover that most of the current anti-drug advertising is useless. They create their... View Details
- October 1987 (Revised March 1992)
- Supplement
Boston Fights Drugs (B): Converting Research to Action
By: V. Kasturi Rangan and Jennifer Lawrence
Describes the results of the advertising pre-test described in the (A) case. The group must now decide how to implement its findings for maximum impact. View Details
- July 1981 (Revised October 1992)
- Case
Chipman-Union, Inc.: Odor-Eaters Socks
By: John A. Quelch
The company is considering whether or not to introduce a branded line of men's athletic socks. Considers a preliminary marketing program, including supermarket and drug store distribution. View Details
- December 1976 (Revised September 1980)
- Case
Drug Fair, Inc. (A)
By: John P. Kotter and Leonard A. Schlesinger
- Research Summary
AIDS in Africa: Life, Death and Property Rights
By: Debora L. Spar
In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought... View Details
- Teaching Interest
Overview
By: Leemore S. Dafny
U.S. Healthcare Strategy
The U.S. healthcare sector accounts for 17 percent of GDP, and encompasses a diverse set of industries with public, nonprofit, and for-profit buyers and sellers. There are significant concerns about high and rising spending, and... View Details